Evidence map›Paper›PMID 41650176›Full record

ArticlePLoS pathogens2026

B Cell Receptor's function in virus entry: Anti-SARS-CoV-2 B cell receptors can mediate viral entry in an ACE2-independent mechanism.

Rene Larios, Md Belal Hossain, Rebecca Brown, Arjit Vijey Jeyachandran, Angel Elma Abu, Anne Kathrin Zaiss, Christina M Ramirez, Masakazu Kamata, Steve Cole, Ting-Ting Wu and 3 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rene LariosDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.
Md Belal HossainDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.
Rebecca BrownDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, California, United States of America.
Arjit Vijey JeyachandranDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, California, United States of America.
Angel Elma AbuDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California, United States of America.
Anne Kathrin ZaissDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, California, United States of America.
Christina M RamirezDepartment of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, California, United States of America.
Masakazu KamataDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Steve ColeDepartments of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, United States of America.
Ting-Ting WuUCLA AIDS Institute, David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.
Kenneth DorshkindDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, United States of America.
Vaithilingaraja ArumugaswamiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, California, United States of America.
Kouki MorizonoDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.ORCID https://orcid.org/0000-0001-5601-3992

Funding

Tollip inhibits IL-33 signaling during airway influenza virus infectionU19AI125357 · NIAID · UNIVERSITY OF ARIZONA · PI CARR, TARA F · 2016 to 2025
$14.7M
Viral Immunology CoreU19AI149504 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, IRVIN S.Y., KITCHEN, SCOTT G · 2020 to 2024
$14.3M
Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicityR01DK132735 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARUMUGASWAMI, VAITHILINGARAJA, DEB, ARJUN · 2021 to 2023
$6.0M
Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infectionR01EY032149 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vaithilingaraja Arumugaswami, Ashok Kumar · 2021 to 2026
$2.8M
Developing three-dimensional antisense oligonucleotide drugs against COVID-19R01AI163216 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GUO, FENG · 2021 to 2025
$2.3M
B-cell-specific transduction for anti-HIV antibody and B-cell receptor expressionR01AI145044 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORIZONO, KOKI · 2019 to 2023
$1.9M
The roles of phosphatidylserine and its receptors in HIV replicationR01AI108400 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORIZONO, KOKI · 2013 to 2016
$1.4M
The role of envelope phosphatidylserine in the binding of HIV to target cellsR21AI095004 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORIZONO, KOKI · 2011 to 2012
$424k
NEI NIH HHS R01 EY032149NIAID NIH HHS R01 AI108400NIAID NIH HHS R01 AI145044NIAID NIH HHS R01 AI163216NIAID NIH HHS R21 AI095004NIAID NIH HHS U19 AI125357NIAID NIH HHS U19 AI149504NIDDK NIH HHS R01 DK132735
6 · The paper itself

Abstract

B cells play a crucial role in humoral immunity, acting as sentinels against viral infections by using their B cell receptors (BCRs) to recognize viral proteins. This recognition typically triggers a response leading to the production of neutralizing antibodies against viral surface proteins, such as the viral envelope proteins. However, recent studies have revealed a surprising dual role for BCRs, showing that some enveloped viruses and viral vectors, such as Dengue virus and lentiviral vectors, can exploit anti-viral BCRs as their attachment and entry receptors to infect/transduce B cells. While these viruses use a simple low-pH-dependent fusion mechanism for entry, it remained unclear whether BCRs could facilitate the entry of viruses with more complex fusion requirements, such as HIV-1 and SARS-CoV-2, which rely on their cognate receptors to activate their fusion machinery. In this study, we investigated the ability of BCRs to mediate viral entry for HIV-1 and SARS-CoV-2, which require specific host receptors (CD4 and ACE2, respectively) to activate their fusion machinery. We found that while anti-HIV-1 envelope protein BCRs can mediate viral attachment, they are unable to facilitate viral fusion and entry. In contrast, anti-SARS-CoV-2 Spike (S) protein BCRs not only mediate attachment but also enable viral entry in the absence of the ACE2 receptor. Our findings demonstrate that the ability of anti-viral BCRs to mediate viral fusion/entry is not universal but depends on the specific viral envelope protein. This novel entry pathway has important implications for both viral replication and the development of B cell-mediated immunity.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19Receptors, Antigen, B-CellSARS-CoV-2Virus InternalizationAnimalsB-LymphocytesHIV-1HumansACE2 protein, humanAngiotensin-Converting Enzyme 2Receptors, Antigen, B-Cell

Identifiers

PMID41650176
PMCPMC12893656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.